MAIA Biotechnology, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Nature of Business and Summary of Significant Accounting Policies (Tables)

Nature of Business and Summary of Significant Accounting Policies (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Antidilutive Shares Excluded from Calculation of Dilutive Loss Per Share

The following table summarizes the Company’s potentially dilutive securities, in common share equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive:


	Three Months Ended March 31,
	2023		2022
Shares issuable upon exercise of stock options		7,217,915		5,859,589
Shares issuable upon exercise of warrants		796,985		1,250,006
Unvested restricted stock awards		—		29,168


	Years Ended December 31,
	2022		2021
Shares issuable upon exercise of stock options		6,545,628		5,797,185
Shares issuable upon exercise of warrants		796,985		1,311,117
Unvested restricted stock awards		—		58,333